John Richard Guyton | Scholars@Duke

John Richard Guyton
Professor of Medicine

Current research efforts focus on the role of niacin in clinical lipid practice. Despite the ending of a large clinical trial due to lack of benefit, niacin remains the second best lipid-modifying drug after statins. Why this trial did not replicate earlier success with niacin is a matter of great interest. Counterregulatory hormone responses may provide the answer. Another research focus is weight loss counseling in the busy clinic setting. Low glycemic dietary advice achieved average long-term weight loss of 3% (beyond 1 year) in a recently published study. One in four patients had long-term weight loss greater than 6%.

Dr. Guyton is recognized nationally as an expert in clinical management of lipid disorders and a leader in postgraduate education in this area. Both nationally and internationally, Dr. Guyton is known for his earlier work on lipid deposition in the arterial wall.

Key words: atherosclerosis, lipoproteins, statins, niacin, triglycerides, low density lipoproteins, high density lipoproteins

Current Appointments & Affiliations

Professor of Medicine, Medicine, Endocrinology, Metabolism, and Nutrition, Medicine 2015
Assistant Professor of Pathology, Pathology, Clinical Science Departments 1994

Contact Information

281 Baker House, Brown Zone-Duke South, Durham, NC 27710
Duke Box 3510, Durham, NC 27710
john.guyton@duke.edu (919) 684-4821

Background
Education, Training, & Certifications
- Research Fellowship, Pathology, Harvard Medical School 1977 - 1979
- Resident, Medicine, UT Southwestern Medical School 1974 - 1976
- Intern, Medicine, UT Southwestern Medical School 1973 - 1974
- M.D., Harvard University 1973
- B.S., University of Mississippi 1969
Duke Appointment History
- Associate Professor of Medicine, Medicine, Endocrinology, Metabolism, and Nutrition, Medicine 1993 - 2015
- Medical Center Instructor, Medicine, Clinical Science Departments 1992 - 1993
Recognition
In the News
- AUG 31, 2015 WTVD
  
  New cholesterol drug restores hope for patients
Research
Selected Grants
- EFC13786: Efficacy and Safety of Alirocumab in Patients with Primary Hypercholesterolemia not Treated with a Statin awarded by Sanofi US 2014 - 2018
- ODYSSEY OLE - LTS13463 : Open-Label Extension of EFC12492 and EFC12732 awarded by Sanofi US 2014 - 2018
- Lipoprotein Oxidation And Atherosclerosis awarded by National Institutes of Health 1991 - 1995
- Lipid-Rich Regions In Atherosclerosis awarded by National Institutes of Health 1993
- Arterial Wall And Lipid Deposition awarded by National Institutes of Health 1992 - 1993
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Guyton, JR. "From the editor: Humans are animals and therefore make saturated fat(Accepted)." Journal of Clinical Lipidology (January 1, 2019). Full Text
  - Dufour, R, Hovingh, GK, Guyton, JR, Langslet, G, Baccara-Dinet, MT, Din-Bell, C, Manvelian, G, and Farnier, M. "Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial." Journal of Clinical Lipidology (November 30, 2018). Full Text
  - Farnier, M, Hovingh, GK, Langslet, G, Dufour, R, Baccara-Dinet, MT, Din-Bell, C, Manvelian, G, and Guyton, JR. "Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program." Atherosclerosis 278 (November 2018): 307-314. Full Text
  - Guyton, JR. "From the editor: Lessons from the East." Journal of Clinical Lipidology 12, no. 6 (November 2018): 1331-1332. Full Text
  - Hovingh, GK, Guyton, JR, Langslet, G, Dufour, R, Baccara-Dinet, MT, Din-Bell, C, Manvelian, G, and Farnier, M. "Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia." Journal of Clinical Lipidology 12, no. 6 (November 2018): 1463-1470. Full Text
  - Marcovina, SM, Moriarty, PM, Koschinsky, ML, and Guyton, JR. "JCL roundtable-Lipoprotein(a): The emerging risk factor." Journal of Clinical Lipidology 12, no. 6 (November 2018): 1335-1345. (Review) Full Text
  - Brinton, EA, Ballantyne, CM, Guyton, JR, Philip, S, Doyle, RT, Juliano, RA, and Mosca, L. "Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis." Journal of Women'S Health (2002) 27, no. 9 (September 2018): 1170-1176. Full Text
  - Cuchel, M, Rohatgi, A, Sacks, FM, and Guyton, JR. "JCL roundtable: High-density lipoprotein function and reverse cholesterol transport." Journal of Clinical Lipidology 12, no. 5 (September 2018): 1086-1094. (Review) Full Text
  - Guyton, JR. "From the editor: What is the bottom line for clinical lipidology research?." Journal of Clinical Lipidology 12, no. 5 (September 2018): 1083-1084. Full Text
  - Bittner, VA, Giugliano, RP, Brinton, EA, and Guyton, JR. "PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease." Journal of Clinical Lipidology 12, no. 4 (July 2018): 835-843. (Review) Full Text
  - Guyton, JR. "From the editor: O Canada! A tariff-free zone for scientific exchange." Journal of Clinical Lipidology 12, no. 4 (July 2018): 831-832. Full Text
  - Severson, T, Kris-Etherton, PM, Robinson, JG, and Guyton, JR. "Roundtable discussion: Dietary fats in prevention of atherosclerotic cardiovascular disease." Journal of Clinical Lipidology 12, no. 3 (May 14, 2018): 574-582. (Review) Full Text
  - Guyton, JR. "Old news and a new order." Journal of Clinical Lipidology 12, no. 3 (May 2018): 571-null. Full Text
  - Guyton, JR. "From the editor: Weighing the advantages of lipid conference and journal." Journal of Clinical Lipidology 12, no. 2 (March 2018): 251-252. Full Text
  - Otvos, JD, Guyton, JR, Connelly, MA, Akapame, S, Bittner, V, Kopecky, SL, Lacy, M, Marcovina, SM, Muhlestein, JB, and Boden, WE. "Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial." Journal of clinical lipidology (January 12, 2018). Full Text
  - Guyton, JR. "From the editor: A run of success in treating atherosclerotic vascular disease." Journal of clinical lipidology 12, no. 1 (January 2018): 1-2. Full Text
  - Amrock, SM, Duell, PB, Knickelbine, T, Martin, SS, O'Brien, EC, Watson, KE, Mitri, J, Kindt, I, Shrader, P, Baum, SJ, Hemphill, LC, Ahmed, CD, Andersen, RL, Kullo, IJ, McCann, D, Larry, JA, Murray, MF, Fishberg, R, Guyton, JR, Wilemon, K, Roe, MT, Rader, DJ, Ballantyne, CM, Underberg, JA, Thompson, P, Duffy, D, Linton, MF, Shapiro, MD, Moriarty, PM, Knowles, JW, and Ahmad, ZS. "Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry." Atherosclerosis 267 (December 2017): 19-26. Full Text
  - Guyton, JR. "From the Editor." Journal of clinical lipidology 11, no. 6 (November 2017): 1297-. Full Text
  - Superko, HR, Zhao, X-Q, Hodis, HN, and Guyton, JR. "Niacin and heart disease prevention: Engraving its tombstone is a mistake." Journal of clinical lipidology 11, no. 6 (November 2017): 1309-1317. (Review) Full Text
  - Guyton, JR. "Marine omega-3 fatty acids and cardiac death." Journal of Clinical Lipidology 11, no. 5 (September 2017): 1124-1125. Full Text
  - Guyton, JR. "From the Editor." Journal of clinical lipidology 11, no. 5 (September 2017): 1109-. Full Text
  - Sabatine, MS, Giugliano, RP, Keech, AC, Honarpour, N, Wiviott, SD, Murphy, SA, Kuder, JF, Wang, H, Liu, T, Wasserman, SM, Sever, PS, Pedersen, TR, and FOURIER Steering Committee and Investigators, . "Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease." The New England Journal of Medicine 376, no. 18 (May 2017): 1713-1722. Full Text
  - Mosca, L, Ballantyne, CM, Bays, HE, Guyton, JR, Philip, S, Doyle, RT, and Juliano, RA. "Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials)." The American journal of cardiology 119, no. 3 (February 2017): 397-403. Full Text
  - Gann, DS, Yates, FE, Marsh, DJ, Smith, SW, Ookhtens, M, Bergman, RN, Kraegen, EW, Lazarus, L, Foster, RO, Tan, MH, Guyton, JR, and Soeldner, JS. "REGULATION AND CONTROL IN PHYSIOLOGICAL SYSTEMS." (January 1, 2017).
  - Ginsberg, HN, Rader, DJ, Raal, FJ, Guyton, JR, Baccara-Dinet, MT, Lorenzato, C, Pordy, R, and Stroes, E. "Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher." Cardiovascular Drugs and Therapy 30, no. 5 (October 2016): 473-483. Full Text
  - Stroes, E, Guyton, JR, Lepor, N, Civeira, F, Gaudet, D, Watts, GF, Baccara-Dinet, MT, Lecorps, G, Manvelian, G, Farnier, M, and ODYSSEY CHOICE II Investigators, . "Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study." Journal of the American Heart Association 5, no. 9 (September 13, 2016). Full Text
  - Goldberg, RB, Bittner, VA, Dunbar, RL, Fleg, JL, Grunberger, G, Guyton, JR, Leiter, LA, McBride, R, Robinson, JG, Simmons, DL, Wysham, C, Xu, P, and Boden, WE. "Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH." The American journal of medicine 129, no. 7 (July 2016): 753.e13-753.e22. Full Text
  - Lakey, WC, Greyshock, NG, Kelley, CE, Siddiqui, MA, Ahmad, U, Lokhnygina, YV, and Guyton, JR. "Statin intolerance in a referral lipid clinic." Journal of Clinical Lipidology 10, no. 4 (July 2016): 870-879.e3. Full Text
  - Maki, KC, Guyton, JR, Orringer, CE, Hamilton-Craig, I, Alexander, DD, and Davidson, MH. "Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia." Journal of Clinical Lipidology 10, no. 4 (July 2016): 905-914. Full Text
  - Moriarty, PM, Thompson, PD, Cannon, CP, Guyton, JR, Bergeron, J, Zieve, FJ, Bruckert, E, Jacobson, TA, Kopecky, SL, Baccara-Dinet, MT, Du, Y, Pordy, R, Gipe, DA, and ODYSSEY ALTERNATIVE Investigators, . "Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial." Journal of Clinical Lipidology 9, no. 6 (November 2015): 758-769. Full Text
  - Naggie, S, Patel, K, Yang, L-Y, Chow, S-C, Johnson, V, Guyton, JR, Muir, AJ, Sulkowski, M, and Hicks, C. "Antiretroviral Effects on Host Lipoproteins Are Associated With Changes in Hepatitis C Virus (HCV) RNA Levels in Human Immunodeficiency Virus/HCV Coinfected Individuals." Open forum infectious diseases 2, no. 2 (April 2015): ofv066-. Full Text
  - Santos, RD, Duell, PB, East, C, Guyton, JR, Moriarty, PM, Chin, W, and Mittleman, RS. "Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension." European Heart Journal 36, no. 9 (March 2015): 566-575. Full Text
  - Moriarty, PM, Jacobson, TA, Bruckert, E, Thompson, PD, Guyton, JR, Baccara-Dinet, MT, and Gipe, D. "Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial." Journal of Clinical Lipidology 8, no. 6 (November 2014): 554-561. Full Text
  - McDonnell, DP, Park, S, Goulet, MT, Jasper, J, Wardell, SE, Chang, C-Y, Norris, JD, Guyton, JR, and Nelson, ER. "Obesity, cholesterol metabolism, and breast cancer pathogenesis." Cancer Research 74, no. 18 (September 2014): 4976-4982. Full Text
  - Guyton, JR, Bays, HE, Grundy, SM, Jacobson, TA, and The National Lipid Association Statin Intolerance Panel, . "An assessment by the Statin Intolerance Panel: 2014 update." Journal of Clinical Lipidology 8, no. 3 Suppl (May 2014): S72-S81. Full Text
  - Guyton, JR, Campbell, KB, and Lakey, WC. "Statin intolerance: more questions than answers." Expert Rev Clin Pharmacol 7, no. 1 (January 2014): 1-3. Full Text Link to Item
  - Guyton, JR. "MR spectroscopy of cholesteryl ester in human atherosclerosis." JACC Cardiovasc Imaging 6, no. 12 (December 2013): 1285-1286. Full Text Link to Item
  - Guyton, JR, Slee, AE, Anderson, T, Fleg, JL, Goldberg, RB, Kashyap, ML, Marcovina, SM, Nash, SD, O'Brien, KD, Weintraub, WS, Xu, P, Zhao, X-Q, and Boden, WE. "Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes)." Journal of the American College of Cardiology 62, no. 17 (October 2013): 1580-1584. Full Text
  - Keating, AJ, Campbell, KB, and Guyton, JR. "Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy." The Annals of Pharmacotherapy 47, no. 3 (March 12, 2013): 398-404. (Review) Full Text
  - "Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy." Annals of Pharmacotherapy 47, no. 3 (March 1, 2013): 398-404. Full Text
  - Cziraky, MJ, Willey, VJ, McKenney, JM, Kamat, SA, Fisher, MD, Guyton, JR, Jacobson, TA, and Davidson, MH. "Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting." Journal of Clinical Lipidology 7, no. 2 (March 2013): 102-108. Full Text
  - Lakey, WC, Greyshock, N, and Guyton, JR. "Adverse reactions of Achilles tendon xanthomas in three hypercholesterolemic patients after treatment intensification with niacin and bile acid sequestrants." J Clin Lipidol 7, no. 2 (March 2013): 178-181. Full Text Link to Item
  - Cziraky, MJ, Willey, VJ, McKenney, JM, Kamat, SA, Fisher, MD, Guyton, JR, Jacobson, TA, and Davidson, MH. "Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting." Journal of Clinical Lipidology 7, no. 2 (2013): 102-108. Full Text
  - Farnier, M, Guyton, JR, Jensen, E, Polis, AB, Johnson-Levonas, AO, and Brudi, P. "Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia." Atherosclerosis 229, no. 2 (2013): 415-422. Full Text
  - Okorodudu, DE, Crowley, MJ, Sebastian, S, Rowell, JV, and Guyton, JR. "Inherited lipemic splenomegaly and the spectrum of apolipoprotein e p.Leu167del mutation phenotypic variation." Journal of Clinical Lipidology 7, no. 6 (January 1, 2013): 566-572. (Review) Full Text
  - Chiba-Falek, O, Linnertz, C, Guyton, J, Gardner, SD, Roses, AD, McCarthy, JJ, and Patel, K. "Pleiotropy and allelic heterogeneity in the TOMM40-APOE genomic region related to clinical and metabolic features of hepatitis C infection." Hum Genet 131, no. 12 (December 2012): 1911-1920. Full Text Link to Item
  - Guyton, JR, Fazio, S, Adewale, AJ, Jensen, E, Tomassini, JE, Shah, A, and Tershakovec, AM. "Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial." Diabetes Care 35, no. 4 (April 2012): 857-860. Full Text Link to Item
  - Rowell, J, Thompson, AJ, Guyton, JR, Lao, XQ, McHutchison, JG, McCarthy, JJ, and Patel, K. "Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis." Hepatol Int 6, no. 2 (April 2012): 475-481. Full Text Link to Item
  - Rajanna, V, Campbell, KB, Leimberger, J, Mohanty, BD, and Guyton, JR. "Elevation of fasting morning glucose relative to hemoglobin A1c in normoglycemic patients treated with niacin and with statins." Journal of Clinical Lipidology 6, no. 2 (2012): 168-173. Full Text
  - Leiter, LA, Betteridge, DJ, Farnier, M, Guyton, JR, Lin, J, Shah, A, Johnson-Levonas, AO, and Brudi, P. "Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials." Diabetes, Obesity & Metabolism 13, no. 7 (July 2011): 615-628. Full Text
  - Guyton, JR, Betteridge, DJ, Farnier, M, Leiter, LA, Lin, J, Shah, A, Johnson-Levonas, AO, and Brudi, P. "Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes." Diab Vasc Dis Res 8, no. 2 (April 2011): 160-172. Full Text Link to Item
  - Benjamin, AM, Suchindran, S, Pearce, K, Rowell, J, Lien, LF, Guyton, JR, and McCarthy, JJ. "Gene by sex interaction for measures of obesity in the framingham heart study." J Obes 2011 (2011): 329038-. Full Text Link to Item
  - Roberts, WC, Jr, AMG, Guyton, J, Larosa, J, and Viggiani, R. "The editor's roundtable: Closing the clinical practice gapusing evidence-based treatments for managing lipids." American Journal of Cardiology 107, no. 2 (2011): 230-242. Full Text
  - Bailey, WA, Westman, EC, Marquart, ML, and Guyton, JR. "Low glycemic diet for weight loss in hypertriglyceridemic patients attending a lipid clinic." J Clin Lipidol 4, no. 6 (November 2010): 508-514. Full Text Link to Item
  - Guyton, JR. "Combination regimens with statin, niacin, and intestinally active LDL-lowering drugs: alternatives to high-dose statin therapy?." Curr Opin Lipidol 21, no. 4 (August 2010): 372-377. (Review) Full Text Link to Item
  - Li, JH, Lao, XQ, Tillmann, HL, Rowell, J, Patel, K, Thompson, A, Suchindran, S, Muir, AJ, Guyton, JR, Gardner, SD, McHutchison, JG, and McCarthy, JJ. "Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection." Hepatology 51, no. 6 (June 2010): 1904-1911. Full Text Link to Item
  - Goldberg, RB, Guyton, JR, Mazzone, T, Weinstock, RS, Polis, AB, Tipping, D, Tomassini, JE, and Tershakovec, AM. "Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia." Diabetes Care 33, no. 5 (May 2010): 1021-1024. Full Text
  - Suchindran, S, Rivedal, D, Guyton, JR, Milledge, T, Gao, X, Benjamin, A, Rowell, J, Ginsburg, GS, and McCarthy, JJ. "Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study. (Published online)" PLoS Genet 6, no. 4 (April 29, 2010): e1000928-. Full Text Open Access Copy Link to Item
  - Fazio, S, Guyton, JR, Polis, AB, Adewale, AJ, Tomassini, JE, Ryan, NW, and Tershakovec, AM. "Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia." The American Journal of Cardiology 105, no. 4 (February 2010): 487-494. Full Text
  - Chiba-Falek, O, Nichols, M, Suchindran, S, Guyton, J, Ginsburg, GS, Barrett-Connor, E, and McCarthy, JJ. "Impact of gene variants on sex-specific regulation of human Scavenger receptor class B type 1 (SR-BI) expression in liver and association with lipid levels in a population-based study. (Published online)" BMC Med Genet 11 (January 19, 2010): 9-. Full Text Open Access Copy Link to Item
  - Fazio, S, Guyton, JR, Lin, J, Tomassini, JE, Shah, A, and Tershakovec, AM. "Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome." Diabetes, Obesity and Metabolism 12, no. 11 (2010): 983-993. Full Text
  - Forman, EJ, Guyton, JR, Filip, SJ, and Price, TM. "Implanted estrogen pellets associated with hypertriglyceridemia, biliary dyskinesia and focal nodular hyperplasia of the liver: a case report." J Reprod Med 55, no. 1-2 (January 2010): 87-90. Link to Item
  - Fazio, S, Guyton, JR, Lin, J, Tomassini, JE, Shah, A, and Tershakovec, AM. "Long-term ezetimibe/simvastatin (E/S) plus extended release niacin (N) treatment in hyperlipidaemic patients with diabetes and metabolic syndrome." DIABETOLOGIA 52 (September 2009): S483-S483. Link to Item
  - Tomassini, JE, Mazzone, T, Goldberg, RB, Guyton, JR, Weinstock, RS, Polis, A, Jensen, E, and Tershakovec, AM. "Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia." Diabetes, Obesity & Metabolism 11, no. 9 (September 2009): 855-864. Full Text
  - Brown, WV, Goldberg, AC, Guyton, JR, and Knopp, RH. "The use of niacin." J Clin Lipidol 3, no. 2 (April 2009): 65-69. Full Text Link to Item
  - Guyton, JR, and Simmons, PD. "Flushing and other dermatologic adverse events associated with extended-release niacin therapy." J Clin Lipidol 3, no. 2 (April 2009): 101-108. Full Text Link to Item
  - Brown, BG, Canner, PL, McGovern, ME, Guyton, JR, and Carlson, LA. "Nicotinic Acid." (2009): 298-314. Full Text
  - Guyton, JR, and Goldberg, AC. "Bile Acid Sequestrants." (2009): 281-287. Full Text
  - Fazio, S, Brown, BG, Guyton, JR, Polis, A, Tomassini, J, and Tershakovec, AM. "Triple combination Ezetimibe/Simvastatin plus extended release Niacin therapy improves ratios of ApoB/ApoA-I containing lipoproteins in hyperlipidemia patients." EUROPEAN HEART JOURNAL 29 (September 2008): 345-346. Link to Item
  - Lien, LF, and Guyton, JR. "Metabolic syndrome." Dermatol Ther 21, no. 5 (September 2008): 362-375. (Review) Full Text Link to Item
  - Tomassini, JE, Mazzone, T, Goldberg, RB, Guyton, JR, Weinstock, RS, Polis, A, and Tershakovec, AM. "Effect of ezctimibe/sinivastatin (E/S) versus atorvastatin (A) on lipoprotein subclasses in type 2 diabetes (T2DM) patients with hypercholesterolaemia (HC)." DIABETOLOGIA 51 (September 2008): S339-S339. Link to Item
  - Brown, BG, Fazio, S, Guyton, JR, Polis, A, Tomassini, JE, and Tershakovec, AM. "TIME AND DOSE-RELATED EFFECTS ON THE LIPID PROFILE IN HYPERLIPIDEMIA PATIENTS FOLLOWING TRIPLE COMBINATION THERAPY WITH EZETIMIBE/SIMVASTATIN + NIACIN." Atherosclerosis Supplements 9, no. 1 (May 2008): 186-187. Full Text
  - FAZIO, S, BROWN, B, GUYTON, J, POLIS, A, TOMASSINI, J, and TERSHAKOVEC, A. "EFFICACY AND SAFETY OF EZETIMIBE/SIMVASTATIN COADMINISTERED WITH EXTENDED RELEASE NIACIN IN PATIENTS WITH TYPE IIA OR IIB HYPERLIPIDEMIA." Atherosclerosis Supplements 9, no. 1 (May 2008): 16-16. Full Text
  - Guyton, JR, Brown, BG, Fazio, S, Polis, A, Tomassini, JE, and Tershakovec, AM. "SAFETY AND TOLERABILITY OF THE TRIPLE COMBINATION EZETIMIBE/SIMVASTATIN + EXTENDED RELEASE NIACIN IN HYPERLIPIDEMIA PATIENTS." Atherosclerosis Supplements 9, no. 1 (May 2008): 261-261. Full Text
  - Guyton, JR, Brown, BG, Fazio, S, Polis, A, Tomassini, JE, and Tershakovec, AM. "Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia." J Am Coll Cardiol 51, no. 16 (April 22, 2008): 1564-1572. Full Text Link to Item
  - Guyton, JR, Goldberg, RB, Mazzone, T, Weinstock, RS, Polis, A, Rosenberg, E, and Tershakovec, AM. "Lipoprotein and apolipoprotein ratios in the VYTAL trial of ezetimibe/simvastatin compared with atorvastatin in type 2 diabetes." J Clin Lipidol 2, no. 1 (February 2008): 19-24. Full Text Link to Item
  - Brown, WV, Clark, L, Falko, JM, Guyton, JR, Rees, TJ, Schonfeld, G, and Lopes-Virella, MF. "Optimal management of lipids in diabetes and metabolic syndrome." Journal of Clinical Lipidology 2, no. 5 (2008): 335-342. Full Text
  - Jr, VEF, Ballantyne, CM, Davidson, MH, Guyton, JR, and Roberts, WC. "The Editor's Roundtable: Lipid Management Beyond Statins-Reducing Residual Cardiovascular Risk." American Journal of Cardiology 102, no. 5 (2008): 559-567. Full Text
  - Weinstock, RS, Goldberg, RB, Guyton, JR, Mazzone, T, Polis, A, Tomassini, JE, Lin, J, Shah, A, and Tershakovec, AM. "Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes." Journal of Clinical Lipidology 2, no. 1 (2008): 25-35. Full Text
  - Guyton, JR. "Niacin in cardiovascular prevention: mechanisms, efficacy, and safety." Curr Opin Lipidol 18, no. 4 (August 2007): 415-420. (Review) Full Text Link to Item
  - Wang, H, Lynch, JR, Song, P, Yang, H-J, Yates, RB, Mace, B, Warner, DS, Guyton, JR, and Laskowitz, DT. "Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury." Experimental Neurology 206, no. 1 (July 2007): 59-69. Full Text
  - Goldberg, RB, Guyton, JR, Mazzone, T, Weinstock, RS, Polis, A, Edwards, P, Tomassini, JE, and Tershakovec, AM. "Did a Flawed Study Design Affect the Results of the VYTAL Study?–Reply–I." Mayo Clinic Proceedings 82, no. 4 (April 2007): 522-522. Full Text
  - Goldberg, RB, Guyton, JR, Mazzone, T, Weinstock, RS, Polis, A, Edwards, P, Tomassini, JE, and Tershakovec, AM. "Did a flawed study design affect the results of the VYTAL study? Reply." MAYO CLINIC PROCEEDINGS 82, no. 4 (April 2007): 522-522. Full Text Link to Item
  - Guyton, JR, and Bays, HE. "Safety considerations with niacin therapy." The American Journal of Cardiology 99, no. 6A (March 2007): 22C-31C. (Review) Full Text
  - Jacobson, TA, Armani, A, McKenney, JM, and Guyton, JR. "Safety Considerations with Gastrointestinally Active Lipid-Lowering Drugs." American Journal of Cardiology 99, no. 6 SUPPL. 1 (2007): S47-S55. Full Text
  - Goldberg, RB, Guyton, JR, Mazzone, T, Weinstock, RS, Polis, A, Edwards, P, Tomassini, JE, and Tershakovec, AM. "Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study." Mayo Clinic Proceedings 81, no. 12 (December 2006): 1579-1588. Full Text
  - Guyton, JR, Goldberg, RB, Mazzone, T, Weinstock, RS, Polis, A, Rosenberg, E, Edwards, P, and Tershakovec, AM. "Ezetimibe/simvastatin more favorably influences lipoprotein/apolipoprotein ratios than atorvastatin monotherapy in patients with type 2 diabetes." CIRCULATION 114, no. 18 (October 31, 2006): 797-797. Link to Item
  - Weinstock, RS, Goldberg, RB, Guyton, JR, Mazzone, T, Polis, A, Tomassini, JE, Desrosiers, E, and Tershakovec, AM. "Enhanced attainment of optional recommended levels of LDL-C, apolipoprotein B, non-HDL and hsCRP in type 2 diabetes patients treated with ezetimibe/simvastatin compared to atorvastatin." CIRCULATION 114, no. 18 (October 31, 2006): 796-797. Link to Item
  - Westman, EC, Yancy, WS, Olsen, MK, Dudley, T, and Guyton, JR. "Effect of a low-carbohydrate, ketogenic diet program compared to a low-fat diet on fasting lipoprotein subclasses." Int J Cardiol 110, no. 2 (June 16, 2006): 212-216. Full Text Link to Item
  - Goldstein, LB, Adams, R, Alberts, MJ, Appel, LJ, Brass, LM, Bushnell, CD, Culebras, A, DeGraba, TJ, Gorelick, PB, Guyton, JR, Hart, RG, Howard, G, Kelly-Hayes, M, Nixon, JVI, Sacco, RL, American Heart Association, , and American Stroke Association Stroke Council, . "Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group." Circulation 113, no. 24 (June 2006): e873-e923. Full Text
  - Goldstein, LB, Adams, R, Alberts, MJ, Appel, LJ, Brass, LM, Bushnell, CD, Culebras, A, Degraba, TJ, Gorelick, PB, Guyton, JR, Hart, RG, Howard, G, Kelly-Hayes, M, Nixon, JVI, Sacco, RL, American Heart Association/American Stroke Association Stroke Council, , Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group, , Cardiovascular Nursing Council, , Clinical Cardiology Council, , Nutrition, Physical Activity, and and Metabolism Council, et al. "Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline." Stroke 37, no. 6 (June 2006): 1583-1633. Full Text Link to Item
  - Anderson, JJB, Prytherch, SA, Sparling, M, Barrett, C, and Guyton, JR. "The Metabolic Syndrome." Nutrition Today 41, no. 3 (May 2006): 115-122. Full Text
  - Guyton, JR. "Benefit versus risk in statin treatment." Am J Cardiol 97, no. 8A (April 17, 2006): 95C-97C. Full Text Link to Item
  - McKenney, JM, Davidson, MH, Jacobson, TA, Guyton, JR, and National Lipid Association Statin Safety Assessment Task Force, . "Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force." The American Journal of Cardiology 97, no. 8A (April 2006): 89C-94C. Full Text
  - Jelesoff, NE, Ballantyne, CM, Xydakis, AM, Chiou, P, Jones, PH, and Guyton, JR. "Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia." Endocr Pract 12, no. 2 (March 2006): 159-164. Full Text Link to Item
  - Cziraky, MJ, Willey, VJ, McKenney, JM, Kamat, SA, Fisher, MD, Guyton, JR, Jacobson, TA, and Davidson, MH. "Statin Safety: An Assessment Using an Administrative Claims Database." American Journal of Cardiology 97, no. 8 SUPPL. 1 (2006): S61-S68. Full Text
  - Miranda, PJ, DeFronzo, RA, Califf, RM, and Guyton, JR. "Metabolic syndrome: definition, pathophysiology, and mechanisms." American Heart Journal 149, no. 1 (January 2005): 33-45. Full Text
  - Miranda, PJ, DeFronzo, RA, Califf, RM, and Guyton, JR. "Metabolic syndrome: evaluation of pathological and therapeutic outcomes." American Heart Journal 149, no. 1 (January 2005): 20-32. Full Text
  - Guyton, JR. "Extended-release niacin for modifying the lipoprotein profile." Expert Opin Pharmacother 5, no. 6 (June 2004): 1385-1398. (Review) Full Text Link to Item
  - Yancy, WS, Olsen, MK, Guyton, JR, Bakst, RP, and Westman, EC. "A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial." Annals of Internal Medicine 140, no. 10 (May 2004): 769-777. Full Text
  - Waters, DD, Guyton, JR, Herrington, DM, McGowan, MP, Wenger, NK, Shear, C, and TNT Steering Committee Members and Investigators, . "Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?." The American Journal of Cardiology 93, no. 2 (January 2004): 154-158. Full Text
  - Xydakis, AM, Guyton, JR, Chiou, P, Stein, JL, Jones, PH, and Ballantyne, CM. "Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia." American Journal of Cardiology 94, no. 6 (2004): 795-797. Full Text
  - Duvall, WL, Blazing, MA, Saxena, S, and Guyton, JR. "Targeting Cardiovascular Risk Associated with Both Low Density and High Density Lipoproteins Using Statin-niacin Combination Therapy." European Journal of Cardiovascular Prevention & Rehabilitation 9, no. 6 (December 1, 2002): 339-347. Full Text
  - Duvall, WL, Blazing, MA, Saxena, S, and Guyton, JR. "Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy." J Cardiovasc Risk 9, no. 6 (December 2002): 339-347. Full Text Link to Item
  - Guyton, JR. "Clinical assessment of atherosclerotic lesions: Emerging from angiographic shadows." Circulation 106, no. 11 (2002): 1308-1309. Full Text
  - Kashyap, ML, McGovern, ME, Berra, K, Guyton, JR, Jr, POK, Harper, WL, Toth, PD, Favrot, LK, Kerzner, B, Nash, SD, Bays, HE, and Simmons, PD. "Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia*." American Journal of Cardiology 89, no. 6 (2002): 672-678. Full Text
  - Yancy, WS, Guyton, JR, Bakst, RP, Tomlin, KF, Bryson, WH, Perkins, CE, and Westman, EC. "A randomized controlled trial of a very-low-carbohydrate diet with nutritional supplements versus a low-fat/low-calorie diet." OBESITY RESEARCH 9 (September 2001): 184S-184S. Link to Item
  - Guyton, JR. "Phospholipid hydrolytic enzymes in a 'cesspool' of arterial intimal lipoproteins: A mechanism for atherogenic lipid accumulation." Arteriosclerosis, Thrombosis, and Vascular Biology 21, no. 6 (2001): 884-886.
  - Goldberg, A, Alagona, P, Capuzzi, DM, Guyton, J, Morgan, JM, Rodgers, J, Sachson, R, and Samuel, P. "Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia." The American Journal of Cardiology 85, no. 9 (May 2000): 1100-1105. Full Text
  - Guyton, JR, Blazing, MA, Hagar, J, Kashyap, ML, Knopp, RH, McKenney, JM, Nash, DT, and Nash, SD. "Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group." Arch Intern Med 160, no. 8 (April 24, 2000): 1177-1184. Link to Item
  - Bowen, PH, and Guyton, JR. "Nonpharmacologic and pharmacologic treatment of patients with low levels of high-density lipoprotein cholesterol." Curr Atheroscler Rep 2, no. 1 (January 2000): 58-63. (Review) Link to Item
  - Guyton, JR, Blazing, MA, Hagar, J, Kashyap, ML, Knopp, RH, McKenney, JM, Nash, DT, and Nash, SD. "Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol." Archives of Internal Medicine 160, no. 8 (2000): 1177-1184.
  - Guyton, JR. "Combination drug therapy for combined hyperlipidemia." Curr Cardiol Rep 1, no. 3 (September 1999): 244-250. (Review) Link to Item
  - Guyton, JR, Dujovne, CA, and Illingworth, DR. "Dual hepatic metabolism of cerivastatin - Clarifications." American Journal of Cardiology 84, no. 4 (1999): 497--.
  - Guyton, JR. "Treatment of type III hyperlipoproteinemia." American Heart Journal 138, no. 1 I (1999): 17-18. Full Text
  - Perris, AL, Bartel, AG, Maynard, C, Bariciano, R, Gates, KB, Guyton, JR, and Wagner, GS. "Does a high level of HDL-C cholesterol undo the bad effects of a high LDL-C cholesterol?." North Carolina medical journal 60, no. 4 (1999): 217-221.
  - Guyton, JR, and Capuzzi, DM. "Treatment of hyperlipidemia with combined niacin-statin regimens." Am J Cardiol 82, no. 12A (December 17, 1998): 82U-84U. (Review) Link to Item
  - Guyton, JR. "Effect of niacin on atherosclerotic cardiovascular disease." Am J Cardiol 82, no. 12A (December 17, 1998): 18U-23U. (Review) Link to Item
  - Guyton, JR. "Advances in dyslipidemia: discussion session II." The American Journal of Cardiology 82, no. 12 (December 1998): 85U-86U. Full Text
  - Kwiterovich, PO, and Guyton, JR. "Introduction." The American Journal of Cardiology 82, no. 12 (December 1998): 1U-2U. Full Text
  - Bales, CW, Moreno, KL, Guyton, JR, Yunker, PA, McGee, MK, Currie, KL, Brown, S, Kuchibhatla, M, and Drezner, MK. "Comparison of proximate composition and fatty acid and cholesterol content of lean and typical commercial pork." J Am Diet Assoc 98, no. 11 (November 1998): 1328-1330. Full Text Link to Item
  - Guyton, JR, Goldberg, AC, Kreisberg, RA, Sprecher, DL, Superko, HR, and O'Connor, CM. "Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia." Am J Cardiol 82, no. 6 (September 15, 1998): 737-743. Link to Item
  - Matthew, WD, Guyton, JR, Scott, BL, and Strittmatter, WJ. "Apolipoprotein E and neural survival." EXPERIMENTAL NEUROLOGY 151, no. 1 (May 1998): 151-152. Link to Item
  - Guyton, JR, Miller, SE, Martin, ME, Khan, WA, Roses, AD, and Strittmatter, WJ. "Novel large apolipoprotein E-containing lipoproteins of density 1.006-1.060 g/ml in human cerebrospinal fluid." J Neurochem 70, no. 3 (March 1998): 1235-1240. Link to Item
  - Capuzzi, DM, Guyton, JR, Morgan, JM, Goldberg, AC, Kreisberg, RA, Brusco, OA, and Brody, J. "Efficacy and safety of an extended-release niacin (Niaspan): A long- term study." American Journal of Cardiology 82, no. 12 A (1998): 74U-81U. Full Text
  - Guyton, JR, and Capuzzi, DM. "Treatment of hyperlipidemia with combined niacin-statin regimens." American Journal of Cardiology 82, no. 12 A (1998): 82U-84U. Full Text
  - Guyton, JR. "Effect of niacin on atherosclerotic cardiovascular disease." American Journal of Cardiology 82, no. 12 A (1998): 18U-23U. Full Text
  - Morgan, JM, Capuzzi, DM, and Guyton, JR. "A new extended-release niacin (niaspan): Efficacy, tolerability, and safety in hypercholesterolemic patients." American Journal of Cardiology 82, no. 12 A (1998): 29U-34U. Full Text
  - Guyton, JR, OConnor, CM, Goldberg, AC, Kreisberg, RA, Sprecher, DL, and Superko, HR. "Extended-release niacin with or without inhibitors of hydroxymethylglutaryl CoA reductase: Improvement in dyslipidemia with minimal effect on transaminases." ATHEROSCLEROSIS 134, no. 1-2 (October 1997): 56-56. Full Text Link to Item
  - Thompson, PD, Zmuda, JM, Domalik, LJ, Zimet, RJ, Staggers, J, and Guyton, JR. "Lovastatin increases exercise-induced skeletal muscle injury." Metabolism: Clinical and Experimental 46, no. 10 (October 1997): 1206-1210. Full Text
  - Barbeau, ML, Klemp, KF, Guyton, JR, and Rogers, KA. "Dietary fish oil: Influence on lesion regression in the porcine model of atherosclerosis." Arteriosclerosis, Thrombosis, and Vascular Biology 17, no. 4 (1997): 688-694.
  - Kenar, JA, Havrilla, CM, Porter, NA, Guyton, JR, Brown, SA, Klemp, KF, and Selinger, E. "Identification and quantification of regioisomeric cholesteryl linoleate hydroperoxides in oxidized human low density lipoprotein and high density lipoprotein." Chem Res Toxicol 9, no. 4 (June 1996): 737-744. Full Text Link to Item
  - Guyton, JR, and Klemp, KF. "Development of the lipid-rich core in human atherosclerosis." Arterioscler Thromb Vasc Biol 16, no. 1 (January 1996): 4-11. (Review) Link to Item
  - Guyton, JR, Lenz, ML, Mathews, B, Hughes, H, Karsan, D, Selinger, E, and Smith, CV. "Toxicity of oxidized low density lipoproteins for vascular smooth muscle cells and partial protection by antioxidants." Atherosclerosis 118, no. 2 (December 1995): 237-249. Link to Item
  - Bales, C, Moreno, K, Brown, S, Guyton, J, McGee, M, Currie, K, and Drezner, M. "Lean Pork for Lipid-lowering Diets." Journal of the American Dietetic Association 95, no. 9 (September 1995): A57-A57. Full Text
  - Burlet, O, Yang, C-Y, Guyton, JR, and Gaskell, SJ. "Tandem mass spectrometric characterization of a specific cysteic acid residue in oxidized human apoprotein B-100." Journal of the American Society for Mass Spectrometry 6, no. 4 (April 1995): 242-247. Full Text
  - Guyton, JR. "The role of lipoproteins in atherogenesis." Adv Exp Med Biol 369 (1995): 29-38. (Review) Link to Item
  - Guyton, JR. "The arterial wall and the atherosclerotic lesion." Curr Opin Lipidol 5, no. 5 (October 1994): 376-381. (Review) Link to Item
  - Guyton, JR, and Klemp, KF. "Development of the atherosclerotic core region. Chemical and ultrastructural analysis of microdissected atherosclerotic lesions from human aorta." Arteriosclerosis and Thrombosis : a Journal of Vascular Biology 14, no. 8 (August 1994): 1305-1314. Full Text
  - Hughes, H, Mathews, B, Lenz, ML, and Guyton, JR. "Cytotoxicity of oxidized LDL to porcine aortic smooth muscle cells is associated with the oxysterols 7-ketocholesterol and 7-hydroxycholesterol." Arteriosclerosis and Thrombosis : a Journal of Vascular Biology 14, no. 7 (July 1994): 1177-1185. Full Text
  - Stary, HC, Chandler, AB, Glagov, S, Guyton, JR, Insull, W, Rosenfeld, ME, Schaffer, SA, Schwartz, CJ, Wagner, WD, and Wissler, RW. "A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association." Circulation 89, no. 5 (May 1994): 2462-2478. (Review) Full Text
  - Stary, HC, Chandler, AB, Glagov, S, Guyton, JR, Insull, W, Rosenfeld, ME, Schaffer, SA, Schwartz, CJ, Wagner, WD, and Wissler, RW. "A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association." Arteriosclerosis and Thrombosis : a Journal of Vascular Biology 14, no. 5 (May 1994): 840-856. (Review) Full Text
  - Daley, SJ, Klemp, KF, Guyton, JR, and Rogers, KA. "Cholesterol-fed and casein-fed rabbit models of atherosclerosis. Part 2: Differing morphological severity of atherogenesis despite matched plasma cholesterol levels." Arteriosclerosis and Thrombosis : a Journal of Vascular Biology 14, no. 1 (January 1994): 105-141. Full Text
  - Siegel, CO, Churchill, DA, Vu, L, Guyton, JR, Minor, ST, and Raizner, AE. "Amiprilose hydrochloride inhibits porcine aortic smooth muscle cell proliferation in vitro." Artery 21, no. 2 (1994): 114-123.
  - Valentinova, NV, Wei, GZ, Manlan, Y, Yanushevskaya, EV, Antonov, IV, Guyton, JR, Smith, CV, Jnr, AMG, and yuh, YC. "Immunoreactivity of apolipoprotein B-100 in oxidatively modified low density lipoprotein." Biological Chemistry Hoppe-Seyler 375, no. 10 (1994): 651-658.
  - Guyton, JR, and Klemp, KF. "Transitional features in human atherosclerosis. Intimal thickening, cholesterol clefts, and cell loss in human aortic fatty streaks." Am J Pathol 143, no. 5 (November 1993): 1444-1457. Link to Item
  - Yang, C-Y, Gu, Z-W, Valentinova, N, Pownall, HJ, Lee, B, Yang, M, Xie-, YH, Guyton, JR, Vlasik, TN, Fruchart, J-C, and Jr, AMG. "Human very low density lipoprotein structure: Interaction of the C apolipoproteins with apolipoprotein B-100." Journal of Lipid Research 34, no. 8 (1993): 1311-1321.
  - Guyton, JR, and Klemp, KF. "Early extracellular and cellular lipid deposits in aorta of cholesterol-fed rabbits." American Journal of Pathology 141, no. 4 (1992): 925-936.
  - Guyton, JR, Klemp, KF, and Mims, MP. "Altered ultrastructural morphology of self-aggregated low density lipoproteins: Coalescence of lipid domains forming droplets and vesicles." Journal of Lipid Research 32, no. 6 (1991): 953-962.
  - Podet, EJ, Shaffer, DR, Gianturco, SH, Bradley, WA, Yang, CY, and Guyton, JR. "Interaction of low density lipoproteins with human aortic elastin." Arteriosclerosis and Thrombosis : a Journal of Vascular Biology 11, no. 1 (January 1991): 116-122. Full Text
  - Rodgers, GP, Minor, ST, Robinson, K, Cromeens, D, Stephens, LC, Woolbert, SC, Guyton, JR, Wright, K, Siegel, R, Roubin, GS, and Raizner, AE. "The coronary artery response to implantation of a balloon-expandable flexible stent in the aspirin- and non-aspirin-treated swine model." American Heart Journal 122, no. 3 PART 1 (1991): 640-647. Full Text
  - Guyton, JR, Black, BL, and Seidel, CL. "Focal toxicity of oxysterols in vascular smooth muscle cell culture: A model of the atherosclerotic core region." American Journal of Pathology 137, no. 2 (1990): 425-434.
  - Guyton, JR, Dao, DT, Lindsay, KL, and Taylor, AA. "Ultrastructure of hypertensive rat aorta: Increased basement membrane-like material." Hypertension 15, no. 1 (1990): 56-67.
  - Guyton, JR, Klemp, KF, Black, BL, and Bocan, TMA. "Extracellular lipid deposition in atherosclerosis." European Heart Journal 11, no. SUPPL. E (1990): 20-28.
  - Lenz, ML, Hughes, H, Mitchell, JR, Via, DP, Guyton, JR, Taylor, AA, Jr, AMG, and Smith, CV. "Lipid hydroperoxy and hydroxy derivatives in copper-catalyzed oxidation of low density lipoprotein." Journal of Lipid Research 31, no. 6 (1990): 1043-1050.
  - Rodgers, GP, Minor, ST, Robinson, K, Cromeens, D, Woolbert, SC, Stephens, LC, Guyton, JR, Wright, K, Roubin, GS, and Raizner, AE. "Adjuvant therapy for intracoronary stents: Investigations in atherosclerotic swine." Circulation 82, no. 2 (1990): 560-569.
  - Cushing, GL, Gaubatz, JW, Nava, ML, Burdick, BJ, Bocan, TM, Guyton, JR, Weilbaecher, D, DeBakey, ME, Lawrie, GM, and Morrisett, JD. "Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation." Arteriosclerosis (Dallas, Tex.) 9, no. 5 (September 1989): 593-603. Full Text
  - Guyton, JR, Shaffer, DR, and Henry, PD. "Stress fibers in endothelial cells overlying atherosclerotic lesions in rabbit aorta." American Journal of the Medical Sciences 298, no. 2 (1989): 79-82.
  - Guyton, JR, and Klemp, KF. "The lipid-rich core region of human atherosclerotic fibrous plaques. Prevalence of small lipid droplets and vesicles by electron microscopy." American Journal of Pathology 134, no. 3 (1989): 705-717.
  - Bocan, TM, Brown, SA, and Guyton, JR. "Human aortic fibrolipid lesions. Immunochemical localization of apolipoprotein B and apolipoprotein A." Arteriosclerosis (Dallas, Tex.) 8, no. 5 (September 1988): 499-508. Full Text
  - Guyton, JR, and Klemp, KE. "Ultrastructural discrimination of lipid droplets and vesicles in atherosclerosis: Value of osmium-thiocarbohydrazide-osmium and tannic acid-paraphenylenediamine techniques." Journal of Histochemistry and Cytochemistry 36, no. 10 (1988): 1319-1328.
  - Gaubatz, JW, Chari, MV, Nava, ML, Guyton, JR, and Morrisett, JD. "Isolation and characterization of the two major apoproteins in human lipoprotein[a]." Journal of Lipid Research 28, no. 1 (1987): 69-79.
  - Morrisett, JD, Guyton, JR, Gaubatz, JW, and Gotto, AM. "Chapter 4 Lipoprotein(a): structure, metabolism and epidemiology." (1987): 129-152. Full Text
  - Ahmad, TY, Guyton, JR, Sparrow, JT, and Morrisett, JD. "Apolipoprotein C-III/sphingomyelin recombinants: formation, isolation, and characterization." Biochemistry 25, no. 15 (July 1986): 4407-4414. Full Text
  - Bocan, TMA, Schifani, TA, and Guyton, JR. "Ultrastructure of the human aortic fibrolipid lesion. Formation of the atherosclerotic lipid-rich core." American Journal of Pathology 123, no. 3 (1986): 413-424.
  - Dahlen, GH, Guyton, JR, Attar, M, Farmer, JA, Kautz, JA, and Jr, AMG. "Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography." Circulation 74, no. 4 (1986): 758-765.
  - Mims, MP, Guyton, JR, and Morrisett, JD. "Microemulsions of cholesteryl oleate and dimyristoylphosphatidylcholine: A model for cholesteryl ester rich very low density lipoproteins." Biochemistry 25, no. 2 (1986): 474-483.
  - Guyton, JR, Bocan, TM, and Schifani, TA. "Quantitative ultrastructural analysis of perifibrous lipid and its association with elastin in nonatherosclerotic human aorta." Arteriosclerosis (Dallas, Tex.) 5, no. 6 (November 1985): 644-652. Full Text
  - Guyton, JR, Dahlen, GH, Patsch, W, Kautz, JA, and Gotto, AM. "Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B." Arteriosclerosis (Dallas, Tex.) 5, no. 3 (May 1985): 265-272. Full Text
  - Guyton, JR, and Hartley, CJ. "Flow restriction of one carotid artery in juvenile rats inhibits growth of arterial diameter." The American Journal of Physiology 248, no. 4 Pt 2 (April 1985): H540-H546. Full Text
  - "Ultrastructural localization of perifibrous lipid in grossly normal human aortic intima - Role of elastin." Federation Proceedings 44, no. 4 (January 1, 1985).
  - Bocan, TMA, and Guyton, JR. "Human aortic fibrolipid lesions. Progenitor lesions for fibrous plaques, exhibiting early formation of the cholesterol-rich core." American Journal of Pathology 120, no. 2 (1985): 193-206.
  - Guyton, JR, and Hartley, CJ. "Flow restriction of one carotid artery in juvenile rats inhibits growth of arterial diameter." American Journal of Physiology - Heart and Circulatory Physiology 17, no. 4 (1985): H540-H546.
  - Schifani, TA. "Human aortic fibro-lipid lesions: Cholesterol-rich core formation in a fibrous plaque precursor lesion." Federation Proceedings 44, no. 4 (January 1, 1985).
  - Guyton, JR, Dao, DT, and Lindsay, KL. "Endothelial denudation and myointimal thickening in the rat carotid artery induced by the passage of bubbles." Experimental and Molecular Pathology 40, no. 3 (1984): 340-348.
  - Guyton, JR, and Hartley, CJ. "Effects of flow restriction and reduced velocity pulsation on circumferential arterial growth." Federation Proceedings 43, no. 4 (1984): no.-4022.
  - Guyton, JR. "Locational stereology performed within sampling fields in rat aortic wall, a polarized tissue." Journal of Microscopy 135, no. 1 (1984): 103-114.
  - Guyton, JR, Lindsay, KL, and Dao, DT. "Comparison of aortic intima and inner media in young adult versus aging rats. Stereology in a polarized system." American Journal of Pathology 111, no. 2 (1983): 234-246.
  - Guyton, JR. "Smooth muscle growth and cholesterol accumulation in atherogenesis." International review of physiology 26 (1982): 1-49.
  - Gordon, D, Guyton, JR, and Karnovsky, MJ. "Intimal alterations in rat aorta induced by stressful stimuli." Laboratory Investigation 45, no. 1 (1981): 14-27.
  - Guyton, JR, Rosenberg, RD, Clowes, AW, and Karnovsky, MJ. "Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin." Circulation Research 46, no. 5 (1980): 625-634.
  - Guyton, JR, Soeldner, JS, Giner, J, Colton, CK, and Morris, RS. "The development of an implantable electrochemical glucose sensor: response to glucose in bovine serum ultrafiltrate." Hormone and Metabolic Research, Supplement , no. 8 (1979): 24-26.
  - Guyton, JR, and Karnovsky, MJ. "Smooth muscle cell proliferation in the occluded rat carotid artery. Lack of requirement for luminal platelets." American Journal of Pathology 94, no. 3 (1979): 585-602.
  - Guyton, JR, Foster, RO, Soeldner, JS, Tan, MH, Kahn, CB, Koncz, L, and Gleason, RE. "A model of glucose-insulin homeostasis in man that incorporates the heterogeneous fast pool theory of pancreatic insulin release." Diabetes 27, no. 10 (1978): 1027-1042.
  - Guyton, JR, and Willerson, JT. "Peripheral venous platelet aggregates in patients with unstable angina pectoris and acute myocardial infarction." Angiology 28, no. 10 (1977): 695-701.
  - Guyton, JR. "Letter: Role of reverse transcriptase." New England Journal of Medicine 294, no. 16 (1976): 902-903.
  - Guyton, JR, Chang, KW, Aisenberg, S, and Soeldner, JS. "ACTIVITY OF VARIOUS ENDOGENOUS COMPOUNDS AND PHARMACOLOGIC AGENTS AT A GLUCOSE-OXIDIZING PLATINUM ELECTRODE." Medical Instrumentation 9, no. 5 (1975): 227-232.
  - Guyton, JR, and Zumwalt, RE. "Letter: Pneumococcemia with sarcoid-infiltrated spleen." Annals of Internal Medicine 82, no. 6 (1975): 847-848.
  - Foster, RO, Soeldner, JS, Tan, MH, and Guyton, JR. "Short Term Glucose Homeostasis in Man: A Systems Dynamics Model." Journal of Dynamic Systems, Measurement, and Control 95, no. 3 (1973): 308-308. Full Text
  - Gann, DS, Yates, FE, Marsh, DJ, Smith, SW, Ookhtens, M, Bergman, RN, Kraegen, EW, Lazarus, L, Foster, RO, Tan, MH, Guyton, JR, and Soeldner, JS. "REGULATION AND CONTROL IN PHYSIOLOGICAL SYSTEMS."
- Book Sections
  - Guyton, JR, Campbell, KB, and Lakey, WC. "Niacin: Risk Benefits and Role in Treating Dyslipidemias." In Dyslipidemias, 439-452.: Humana Press, 2015. Full Text
  - Guyton, JR. "Disorders of lipid and lipoprotein metabolism." In Garner and Klintworth's Pathobiology of Ocular Disease Part B, Third Edition, 1019-1036. January 1, 2007.
- Conference Papers
  - Ginsberg, HN, Rader, DJ, Raal, FJ, Guyton, JR, Lorenzato, C, Pordy, R, Baccara-Dinet, MT, and Stroes, ES. "ODYSSEY HIGH FH: Efficacy and Safety of Alirocumab in Patients With Severe Heterozygous Familial Hypercholesterolemia." December 2, 2014. Link to Item
  - Moriarty, PM, Thompson, PD, Cannon, CP, Guyton, JR, Bergeron, J, Zieve, FJ, Bruckert, E, Jacobson, TA, Baccara-Dinet, MT, Zhao, J, Pordy, R, and Gipe, D. "ODYSSEY ALTERNATIVE: Efficacy And Safety of the Proprotein Convertase Subtilisin/kexin Type 9 Monoclonal Antibody, Alirocumab, versus Ezetimibe, in Patients With Statin Intolerance as Defined by a Placebo Run-in and Statin Rechallenge Arm." December 2, 2014. Link to Item
  - Farnier, M, Guyton, JR, Jensen, E, Polis, A, Johnson-Levonas, AO, and Brudi, P. "Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia." August 2012. Link to Item
  - Betteridge, J, Guyton, JR, Farnier, M, Leiter, LA, Lin, J, Shah, A, Johnson-Levonas, AO, and Brudi, P. "Greater dissociation of apolipoprotein B and LDL cholesterol targets in diabetes versus non-diabetes patients receiving lipid-lowering therapy." September 2011. Link to Item
  - Betteridge, J, Guyton, JR, Farnier, M, Leiter, LA, Lin, J, Shah, A, Johnson-Levonas, AO, and Brudi, P. "MORE AGGRESSIVE LDL-C AND NON-HDL-C TARGETS MUST BE ACHIEVED IN PATIENTS RECEIVING LIPID-LOWERING THERAPY TO NORMALIZE APOB-CONTAINING LIPOPROTEINS." June 2011. Full Text Link to Item
  - Brown, WV, Fazio, S, Guyton, JR, Dong, Q, Tomassini, JE, Shah, A, and Tershakovec, AM. "RELATIONSHIPS BETWEEN HSCRP REDUCTION AND LDL-C, NON-HDL-C, APOB AND HDL-C IN HYPERLIPIDEMIC PATIENTS TREATED WITH EZETIMIBE/SIMVASTATIN plus EXTENDED-RELEASE NIACIN." June 2011. Full Text Link to Item
  - Fazio, S, Guyton, JR, Lin, J, Tomassini, JE, Shah, A, and Tershakovec, AM. "COMBINATION EZETIMIBE/SIMVASTATIN plus EXTENDED-RELEASE NIACIN THERAPY IMPROVES ATTAINMENT OF RECOMMENDED LDL-C, NON-HDL-C AND APOB LEVELS IN HYPERLIPIDEMIC PATIENTS." June 2011. Full Text Link to Item
  - Benjamin, A, Suchindran, S, Pearce, K, Rowell, J, Lien, LF, Guyton, JR, and McCarthy, JJ. "Gene by Sex Interaction for Body Mass Index in the Framingham Heart Study." June 2010. Link to Item
  - Li, JH, Lao, XQ, Tillmann, H, Rowell, J, Patel, K, Thompson, AJ, Suchindran, S, Muir, AJ, Guyton, JR, Gardner, SD, McHutchison, JG, and McCarthy, J. "INTERFERON LAMBDA GENOTYPE AND LOW SERUM LDL CHOLESTEROL LEVELS IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION." 2010. Full Text Link to Item
  - Rowell, JV, Thompson, AJ, Patel, K, Lao, XQ, Suchindran, S, Guyton, JR, McHutchison, JG, and McCarthy, J. "SERUM APOLIPOPROTEIN CIII LEVELS ARE INDEPENDENTLY ASSOCIATED WITH HEPATIC FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION." October 2009. Link to Item
  - Guyton, JR, Brown, BG, Fazio, S, Lin, J, Polis, A, Tomassini, JE, Shah, A, and Tershakovec, AM. "Effect of ezetimibe/simvastatin (E/S) plus extended-release niacin (N) in type IIa and IIb hyperlipidaemia (HL) patients with diabetes (DM) or metabolic syndrome (MS)." September 2008. Link to Item
  - Guyton, JR. "Understanding and Preventing Atherosclerosis." 2008. Link to Item
  - Goldberg, RB, Guyton, JR, Mazzone, T, Weinstock, RS, Polis, A, Tomassini, JE, and Tershakovec, AM. "PO23-786 ASSOCIATION BETWEEN BASELINE LDL-C, TRIGLYCERIDES, AND HDL-C LEVELS AND THE LIPID-ALTERING AND HS-CRP EFFICACIES OF EZETIMIBE/SIMVASTATIN VERSUS ATORVASTATIN IN TYPE 2 DIABETES PATIENTS: THE VYTAL STUDY." : Elsevier BV, June 2007. Full Text
  - Guyton, JR, Goldberg, RB, Mazzone, T, Weinstock, RS, Polis, A, Rosenberg, E, Edwards, P, and Tershakovec, AM. "PO23-755 EZETIMIBE/SIMVASTATIN MORE FAVORABLY INFLUENCES LIPOPROTEIN/APOLIPOPROTEIN RATIOS THAN ATORVASTATIN MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES." : Elsevier BV, June 2007. Full Text
  - Guyton, JR, Weinstock, RS, Mazzone, T, Goldberg, RB, Polis, A, Rosenberg, E, and Tershakovec, AM. "PO23-734 INFLUENCE OF AGE, GENDER, AND ETHNICITY ON TREATMENT EFFECTS IN THE VYTAL TRIAL OF EZETIMIBE/SIMVASTATIN VS. ATORVASTATIN IN TYPE 2 DIABETICS." : Elsevier BV, June 2007. Full Text
  - Weinstock, RS, Goldberg, RB, Guyton, JR, Mazzone, T, Polis, A, Tomassini, JE, Desrosiers, E, and Tershakovec, AM. "PO23-777 EFFECT OF EZETIMIBE/SIMVASTATIN VERSUS ATORVASTATIN ON ATTAINING RECOMMENDED LEVELS OF LDL-C, APOLIOPROTEIN B, NON-HDL-C AND HS-CRP IN TYPE 2 DIABETES." : Elsevier BV, June 2007. Full Text
  - Mazzone, T, Goldberg, RB, Guyton, JR, Weinstock, RS, Polis, A, Gazzara, RA, Tomassini, JE, and Tershakovec, AM. "The safety and efficacy of ezetimibe/simvastatin (E/S) versus atorvastatin (A) in hypercholesterolaemic (HC) patients with type 2 diabetes (T2DM)." September 2006. Link to Item
  - Guyton, JR. "Su-S1:2 The neurological system and statin safety." : Elsevier BV, January 2006. Full Text
  - Chiou, P, Xydakis, AM, Guyton, JR, Stein, JL, Jones, PH, and Ballantyne, CM. "Efficacy and tolerability of ezetimibe add-on therapy in bile acid sequestrant/niacin-based regimen." May 2004. Link to Item
  - GUYTON, JR, and KLEMP, KF. "SPECIFIC FEATURES OF LIPID DEPOSITS ASSOCIATED WITH ARTERIAL COLLAGEN AND ELASTIN." 1995. Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

In the News

Selected Grants

Selected Publications

Academic Articles

Book Sections

Conference Papers